BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23941675)

  • 1. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
    Kaminaka K; Matsuda J; Nozaki C
    Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide.
    Zou P; Li Y; Huang J; Wu F
    Microbes Infect; 2017 Dec; 19(12):648-654. PubMed ID: 28939356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
    Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
    Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel M2e-multiple antigenic peptide providing heterologous protection in mice.
    Wen F; Ma JH; Yu H; Yang FR; Huang M; Zhou YJ; Li ZJ; Wang XH; Li GX; Jiang YF; Tong W; Tong GZ
    J Vet Sci; 2016 Mar; 17(1):71-8. PubMed ID: 27051342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
    Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
    PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
    Zhou C; Zhou L; Chen YH
    Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.
    De Filette M; Ysenbaert T; Roose K; Schotsaert M; Roels S; Goossens E; Schepens B; Fiers W; Saelens X
    J Gen Virol; 2011 Feb; 92(Pt 2):301-6. PubMed ID: 20965983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate.
    Zeng W; Tan AC; Horrocks K; Jackson DC
    Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.